Halozyme Therapeutics, Inc. (LON:0J2O)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 4.83B |
| Revenue (ttm) | 839.24M |
| Net Income (ttm) | 375.67M |
| Shares Out | n/a |
| EPS (ttm) | 2.91 |
| PE Ratio | 12.86 |
| Forward PE | 8.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 399 |
| Average Volume | 1,313 |
| Open | 53.35 |
| Previous Close | 53.09 |
| Day's Range | 52.79 - 53.55 |
| 52-Week Range | 42.51 - 70.13 |
| Beta | n/a |
| RSI | 40.21 |
| Earnings Date | Aug 5, 2025 |
About Halozyme Therapeutics
Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper... [Read more]
Financial Performance
In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.
Financial numbers in USD Financial StatementsNews
Halozyme Therapeutics: The Waters Become Muddled
Halozyme navigates CMS pricing risks impacting 2028+ revenues, yet strong royalties, FY25 guidance, and margins support stable near-term earnings.
Here's How Much $100 Invested In Halozyme Therapeutics 15 Years Ago Would Be Worth Today
Halozyme Therapeutics (NASDAQ: HALO) has outperformed the market over the past 15 years by 2.54% on an annualized basis producing an average annual return of 14.44%. Currently, Halozyme Therapeutics ...
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 5 Years
Halozyme Therapeutics (NASDAQ: HALO) has outperformed the market over the past 5 years by 4.46% on an annualized basis producing an average annual return of 17.65%. Currently, Halozyme Therapeutics h...
Halozyme to Participate at Upcoming Investor Conferences
SAN DIEGO , May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to participa...
What's Driving the Market Sentiment Around Halozyme Therapeutics?
Halozyme Therapeutics's (NYSE: HALO) short percent of float has risen 12.94% since its last report. The company recently reported that it has 10.69 million shares sold short , which is 11.87% of all ...
Price Over Earnings Overview: Halozyme Therapeutics
Looking into the current session, Halozyme Therapeutics Inc. (NASDAQ: HALO) shares are trading at $53.85, after a 1.05% drop. Over the past month, the stock decreased by 10.78% , but over the past ye...
Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
Opdivo® is the first and only PD-1 inhibitor approved for subcutaneous (SC) use in the European Union SAN DIEGO , May 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) tod...
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Each week, Benzinga's Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention.
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News
Halozyme Therapeutics shares tumbled Tuesday on a new Medicare approach to price negotiations for drugs that use its additive product.
J&J, Halozyme cut at Leerink on price control risk for combo products
Halozyme Therapeutics: Q1 Earnings Reveal A Bigger And Deeper Moat
Here's How Much You Would Have Made Owning Halozyme Therapeutics Stock In The Last 15 Years
Halozyme Therapeutics (NASDAQ: HALO) has outperformed the market over the past 15 years by 4.64% on an annualized basis producing an average annual return of 15.92%. Currently, Halozyme Therapeutics ...
Halozyme sees strong Q1 2025 growth, raises 2025 revenue guidance to $1.2B-$1.28B
Halozyme Therapeutics, Inc. (HALO) Q1 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million ; Adjusted EBIT...
HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
Announcing New $250M Share Repurchase Total Revenue Increased 35% YOY to $265 million and Royalty Revenue Increased 39% YOY to $168 million Net Income Increased 54% YOY to $118 million; Adjusted EBIT...
Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
SAN DIEGO , May 5, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, will present and host inve...
Insights into Halozyme Therapeutics's Upcoming Earnings
Halozyme Therapeutics (NASDAQ: HALO) will release its quarterly earnings report on Tuesday, 2025-05-06. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Halozyme T...
Halozyme Therapeutics: Still Undervalued Ahead Of Earnings
Halozyme’s recurring revenue, product strength, and market resilience point to solid upside even with debt and tariff risks. Find out why HALO stock is a buy.
Alnylam, Halozyme among latest firms to win EU backing for drugs
EMA panel supports Alnylam & Halozyme drugs' marketing approval for rare diseases. Read more here.
Halozyme to Report First Quarter 2025 Financial and Operating Results
SAN DIEGO , April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its first quarter 2025 financial and operating results on Tuesday, Ma...
Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
European Commission (EC) decision on marketing authorization application expected within approximately two months SAN DIEGO , April 28, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ...
Halozyme files patent lawsuit against Merck over injectable Keytruda
Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
Complaint filed in New Jersey alleges Merck uses Halozyme's patented MDASE technology to develop SC Keytruda Halozyme is seeking damages and injunctive relief to stop the infringement SAN DIEGO , Apri...